Ranked #3,927 of 8,699 institutional investors
Ikarian Capital, LLC
Dallas, TX
$440M
US stock portfolio at live prices · today −$4.9M (−1.10%)
Live prices, last trade 10:30 AM ET
- Value at quarter end (Q3 2026)
- $504M
- Change from Q2 2026
- −$106.8M (−17.48%)
- Positions
- 108 · 15 new, 14 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: call options on $168M of stock, put options on $322M. $51.8M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesKOD 12.0%PCVX 5.23%ABVX 4.58%SLN 3.70%AMLX 3.31%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| KOD Kodiak Sciences Inc. | 533,113 | $52.9M | 12.0% | Reduced −50% |
| PCVX Vaxcyte, Inc. | 400,465 | $23.0M | 5.23% | Added +3% |
| ABVX ABIVAX Société Anonyme | 285,909 | $20.2M | 4.58% | Reduced −13% |
| SLN Silence Therapeutics plc | 821,790 | $16.3M | 3.70% | Added +394% |
| AMLX Amylyx Pharmaceuticals, Inc. | 561,459 | $14.6M | 3.31% | Added +378% |
| CLDX Celldex Therapeutics, Inc. | 518,500 | $14.3M | 3.24% | Added +8% |
| ANRO Alto Neuroscience Inc | 482,338 | $12.3M | 2.80% | Added +18% |
| RCUS Arcus Biosciences, Inc. | 734,559 | $11.9M | 2.70% | Added +46% |
| ELVN Enliven Therapeutics, Inc. | 232,055 | $10.9M | 2.47% | Added +83% |
| VERA Vera Therapeutics, Inc. | 400,000 | $10.5M | 2.39% | Added +29% |
| ANIP ANI Pharmaceuticals, Inc. | 149,065 | $10.3M | 2.35% | Reduced −45% |
| COGT Cogent Biosciences, Inc. | 370,084 | $10.1M | 2.29% | Unchanged |
| MAZE Maze Therapeutics, Inc. | 301,402 | $9.6M | 2.18% | Reduced −20% |
| VRDN Viridian Therapeutics, Inc. | 225,000 | $6.9M | 1.58% | Reduced −47% |
| JBIO Jade Biosciences, Inc. | 427,349 | $6.6M | 1.49% | Unchanged |
| TECX Tectonic Therapeutic, Inc. | 306,338 | $6.4M | 1.46% | Added +49% |
| ACOG Alpha Cognition Inc. | 701,259 | $6.2M | 1.41% | Reduced −16% |
| MNPR Monopar Therapeutics Inc. | 86,761 | $5.9M | 1.35% | Added +81% |
| CTNM Contineum Therapeutics, Inc. | 594,666 | $5.3M | 1.20% | Reduced −26% |
| VOR Vor Biopharma Inc. | 250,000 | $4.9M | 1.10% | New |
| CCCC C4 Therapeutics, Inc. | 1,933,000 | $4.8M | 1.09% | Reduced −21% |
| EPRX Eupraxia Pharmaceuticals Inc. | 809,741 | $4.8M | 1.08% | Unchanged |
| OVID Ovid Therapeutics Inc. | 2,119,704 | $4.7M | 1.08% | Reduced −7% |
| ALEC Alector, Inc. | 1,982,606 | $4.7M | 1.07% | Unchanged |
| IMNM Immunome, Inc. | 285,000 | $4.7M | 1.06% | Added +375% |
| RLMD Relmada Therapeutics, Inc. | 1,448,359 | $4.2M | 0.96% | Reduced −33% |
| ORIC ORIC Pharmaceuticals, Inc. | 522,765 | $4.1M | 0.93% | New |
| SPRB Spruce Biosciences, Inc. | 101,356 | $4.0M | 0.91% | Reduced −16% |
| IRLA IRulya Therapeutics Inc. | 95,652 | $3.9M | 0.89% | Added +32% |
| SEPN Septerna, Inc. | 100,047 | $3.9M | 0.88% | New |
| IVA Inventiva S.A. | 1,129,101 | $3.8M | 0.86% | Unchanged |
| RZLT Rezolute, Inc. | 935,012 | $3.8M | 0.85% | Unchanged |
| CAMP Camp4 Therapeutics Corp | 912,906 | $3.7M | 0.83% | New |
| FRNM Freenome, Inc. | 362,626 | $3.4M | 0.78% | New |
| CPIX Cumberland Pharmaceuticals Inc. | 503,153 | $3.2M | 0.73% | Unchanged |
| CRDL Cardiol Therapeutics Inc. | 3,325,000 | $2.9M | 0.65% | Unchanged |
| QTTB Q32 Bio Inc. | 345,000 | $2.9M | 0.65% | Reduced −20% |
| OCGN Ocugen, Inc. | 3,562,972 | $2.8M | 0.64% | Reduced −10% |
| VOGX Vogenx, Inc. | 208,836 | $2.8M | 0.63% | New |
| OLMA Olema Oncology, Inc. | 383,281 | $2.7M | 0.62% | Unchanged |
| PEPG PepGen Inc. | 693,539 | $2.7M | 0.61% | Added +55% |
| DCTH Delcath Systems, Inc. | 135,667 | $2.6M | 0.58% | Reduced −27% |
| ARVN Arvinas, Inc. | 358,257 | $2.4M | 0.54% | Unchanged |
| PRAX Praxis Precision Medicines, Inc. | 6,942 | $2.1M | 0.49% | Reduced −90% |
| ACAD Acadia Pharmaceuticals Inc. | 112,000 | $2.0M | 0.45% | Added +299% |
| DNA Ginkgo Bioworks Holdings, Inc. | 250,000 | $2.0M | 0.45% | New |
| OBX Obsidian Therapeutics, Inc. | 158,942 | $1.9M | 0.43% | New |
| DRUG Bright Minds Biosciences Inc. | 88,951 | $1.8M | 0.42% | Unchanged |
| PTHS Pelthos Therapeutics Inc. | 256,598 | $1.8M | 0.41% | Unchanged |
| CAPR Capricor Therapeutics, Inc. | 229,215 | $1.7M | 0.40% | Reduced −62% |
| FTH Faeth Therapeutics, Inc. | 199,694 | $1.7M | 0.39% | Added +464% |
| FULC Fulcrum Therapeutics, Inc. | 449,161 | $1.7M | 0.38% | Reduced −57% |
| LXEO Lexeo Therapeutics, Inc. | 513,011 | $1.6M | 0.37% | Unchanged |
| FDMT 4D Molecular Therapeutics, Inc. | 150,037 | $1.6M | 0.37% | New |
| VSTM Verastem, Inc. | 213,865 | $1.4M | 0.32% | Unchanged |
| IMUX Immunic, Inc. | 182,464 | $1.3M | 0.30% | Added +170% |
| TYRA Tyra Biosciences, Inc. | 65,000 | $1.3M | 0.30% | New |
| KZIA Kazia Therapeutics Limited | 246,201 | $1.3M | 0.29% | Reduced −38% |
| TARS Tarsus Pharmaceuticals, Inc. | 16,858 | $1.3M | 0.29% | Reduced −46% |
| CUE Cue Biopharma, Inc. | 290,633 | $1.2M | 0.28% | Added +178% |
| IVVD Invivyd, Inc. | 2,656,570 | $1.2M | 0.28% | Unchanged |
| RNTX Rein Therapeutics Inc. | 2,950,000 | $1.1M | 0.25% | Unchanged |
| HROW Harrow, Inc. | 33,275 | $1.0M | 0.24% | Reduced −75% |
| STIM Neuronetics, Inc. | 810,182 | $952K | 0.22% | Added +16% |
| DBVT DBV Technologies S.A. | 90,591 | $858K | 0.19% | Reduced −12% |
| DERM Journey Medical Corporation | 251,436 | $850K | 0.19% | Unchanged |
| IBIO iBio, Inc. | 957,062 | $769K | 0.17% | Unchanged |
| LPCN Lipocine Inc. | 508,556 | $748K | 0.17% | Unchanged |
| CABA Cabaletta Bio, Inc. | 700,000 | $707K | 0.16% | Unchanged |
| QNRX Quoin Pharmaceuticals, Ltd. | 211,538 | $703K | 0.16% | Unchanged |
| PMN ProMIS Neurosciences, Inc. | 205,000 | $652K | 0.15% | Unchanged |
| PTN Palatin Technologies, Inc. | 130,000 | $639K | 0.15% | New |
| AVTX Avalo Therapeutics, Inc. | 90,183 | $616K | 0.14% | Unchanged |
| PLRX Pliant Therapeutics, Inc. | 1,000,000 | $599K | 0.14% | Unchanged |
| LYEL Lyell Immunopharma, Inc. | 41,081 | $578K | 0.13% | Unchanged |
| CNSP CNS Pharmaceuticals, Inc. | 135,830 | $500K | 0.11% | Unchanged |
| NMRA Neumora Therapeutics, Inc. | 1,278,408 | $418K | <0.1% | Unchanged |
| PALI Palisade Bio, Inc. | 400,000 | $382K | <0.1% | Reduced −47% |
| EQ Equillium, Inc. | 303,555 | $346K | <0.1% | Unchanged |
| KLRS Kalaris Therapeutics, Inc. | 248,257 | $338K | <0.1% | Reduced −31% |
| ANL Adlai Nortye Group Ltd. | 33,899 | $298K | <0.1% | Unchanged |
| FHTX Foghorn Therapeutics Inc. | 160,000 | $282K | <0.1% | New |
| SLDB Solid Biosciences Inc. | 42,956 | $275K | <0.1% | Unchanged |
| LXRX Lexicon Pharmaceuticals, Inc. | 164,674 | $274K | <0.1% | Unchanged |
| AEON AEON Biopharma, Inc. | 2,203,406 | $274K | <0.1% | New |
| AVR Anteris Technologies Global Corp. | 50,862 | $259K | <0.1% | Reduced −69% |
| SION Sionna Therapeutics, Inc. | 85,300 | $250K | <0.1% | New |
| VKTX Viking Therapeutics, Inc. | 9,717 | $248K | <0.1% | Unchanged |
| PURR Hyperliquid Strategies Inc. | 30,001 | $235K | <0.1% | Unchanged |
| ABOS Acumen Pharmaceuticals, Inc. | 1,053,797 | $185K | <0.1% | Unchanged |
| TENX Tenax Therapeutics, Inc. | 136,648 | $181K | <0.1% | Reduced −83% |
| ALMS Alumis Inc. | 41,177 | $172K | <0.1% | Reduced −95% |
| EVAX Evaxion A/S | 74,698 | $172K | <0.1% | Unchanged |
| MGNX MacroGenics, Inc. | 74,893 | $154K | <0.1% | Unchanged |
| ENVB Enveric Biosciences, Inc. | 100,002 | $144K | <0.1% | Unchanged |
| RNAC Cartesian Therapeutics, Inc. | 20,807 | $129K | <0.1% | Unchanged |
| BCRX BioCryst Pharmaceuticals, Inc. | 16,756 | $122K | <0.1% | Unchanged |
| CMPS COMPASS Pathways plc | 15,000 | $119K | <0.1% | Unchanged |
| PMVP PMV Pharmaceuticals, Inc. | 89,136 | $108K | <0.1% | Unchanged |
| NEUP Neuphoria Therapeutics Inc. | 47,443 | $108K | <0.1% | Unchanged |
| TRAW Traws Pharma, Inc. | 478,142 | $105K | <0.1% | Unchanged |
| VTGN Vistagen Therapeutics, Inc. | 519,077 | $97K | <0.1% | Unchanged |
| VYGR Voyager Therapeutics, Inc. | 53,063 | $86K | <0.1% | Unchanged |
| CMMB Chemomab Therapeutics Ltd. | 51,793 | $66K | <0.1% | Unchanged |
| EYPT EyePoint, Inc. | 205,056 | $52K | <0.1% | New |
| MGRX Mangoceuticals, Inc. | 138,146 | $18K | <0.1% | Unchanged |
| CMPX Compass Therapeutics, Inc. | 18,000 | $13K | <0.1% | Unchanged |
| AIRS AirSculpt Technologies, Inc. | 16,398 | $10K | <0.1% | Unchanged |
Sold out in Q3 2026
| Stock | Shares held at Q2 2026 | Worth today |
|---|---|---|
| BBIO BridgeBio Pharma, Inc. | 57,417 | $4.4M |
| HIMS Hims & Hers Health, Inc. | 188,381 | $2.9M |
| RARE Ultragenyx Pharmaceutical Inc. | 165,617 | $2.8M |
| CLYM Climb Bio Inc | 300,000 | $2.7M |
| ABSI Absci Corporation | 353,772 | $2.7M |
| NXTC NextCure, Inc. | 288,303 | $1.9M |
| TRAX First Tracks Biotherapeutics, Inc. | 42,775 | $1.8M |
| ARWR Arrowhead Pharmaceuticals, Inc. | 38,278 | $1.6M |
| ANNX Annexon, Inc. | 430,244 | $1.4M |
| BIOA BioAge Labs, Inc. | 200,000 | $924K |
| LABD Direxion Daily S&P Biotech Bear 3X Shares | 105,822 | $906K |
| PASG Passage Bio, Inc. | 99,517 | $349K |
| WVE Wave Life Sciences, Inc. | 85,285 | $232K |
| ELTX Elicio Therapeutics, Inc. | 100,000 | $159K |